Assignee
IMMUNSYS INC
US·6 granted patents·4 pending applications·18 citations·filing 2014–2023
Top patents by PatentIndex Score
10 records- 0180US11696797B2Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)IMMUNSYS INC·Filed 2019·Granted Jul 11, 2023·2 cites·30 claims
- 0277US11497544B2Immunologic treatment of cancerIMMUNSYS INC·Filed 2019·Granted Nov 15, 2022·2 cites·25 claims
- 0377US11141216B2Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissueIMMUNSYS INC·Filed 2016·Granted Oct 12, 2021·4 cites·21 claims
- 0476US10849678B2Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)IMMUNSYS INC·Filed 2014·Granted Dec 1, 2020·9 cites·44 claims
- 0573US11612426B2Immunologic treatment of cancerIMMUNSYS INC·Filed 2017·Granted Mar 28, 2023·1 cites·28 claims
- 0669US2024058049A1Immunologic Treatment of CancerIMMUNSYS INC·Filed 2023·Application pending·0 cites
- 0767US12295640B2Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)IMMUNSYS INC·Filed 2020·Granted May 13, 2025·0 cites·15 claims
- 0859US2024156513A1Cancer Immunotherapy by Radiofrequency Electrical Membrane Breakdown (RF-EMB)IMMUNSYS INC·Filed 2023·Application pending·0 cites
- 0958US2022265343A1Radio-Frequency Electrical Membrane Breakdown for the Treatment of High Risk and Recurrent Prostate Cancer, Unresectable Pancreatic Cancer, Tumors of the Breast, Melanoma or Other Skin Malignancies, Sarcoma, Soft Tissue Tumors, Ductal Carcinoma, Neoplasia, and Intra and Extra Luminal Abnormal TissueIMMUNSYS INC·Filed 2021·Application pending·0 cites
- 1044US2019183561A1In situ therapeutic cancer vaccine creation system and methodIMMUNSYS INC·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →